Zenas BioPharma, Inc.
ZBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.28B
Close$
$-2.17
107.5% downside
Current Fair Value
107.5% downsideOvervalued by 107.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.28 Billion |
|---|---|
| Enterprise Value | $1.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.44 |
| Beta | -0.94 |
| Outstanding Shares | 55,624,631 |
Return
| Return on Equity | -126.59% |
|---|---|
| Return on Assets | -56.86% |
| Return on Invested Capital | -37.19% |
Valuation & Multiples
| P/E Ratio | -3.16 |
|---|---|
| PEG | -2.24 |
| Price to Sales | - |
| Price to Book Ratio | 4.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.44 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 1.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$15.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 76.80% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 123.85% |
|---|---|
| Total Invested | $7,665▼ 100.00% |
| Investors Holding | 3▼ 141.00% |
ESG Score
No data
About Zenas BioPharma, Inc.
130 employees
CEO: Mr. Leon Oliver Moulder Jr., M.B.A. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibod...